메뉴 건너뛰기




Volumn 10, Issue 6, 2010, Pages 875-883

Adenovirus vaccine immunotherapy targeting WT1-expressing tumors

Author keywords

Adenovirus; Cancer; Immunotherapy; Vaccine; Wilm's tumor gene; WT1

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; CANCER VACCINE; CD86 ANTIGEN; CONDITIONALLY REPLICATING ADENOVIRUS; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RESTRICTED PEPTIDE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; PEPTIDE VACCINE; PLACEBO; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; WT1 PROTEIN;

EID: 77952209021     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003798278     Document Type: Review
Times cited : (8)

References (75)
  • 1
    • 15444370728 scopus 로고    scopus 로고
    • Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas
    • Park JM, Terabe M, Sakai Y, et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;10(7):4228-4236
    • (2005) J Immunol , vol.10 , Issue.7 , pp. 4228-4236
    • Park, J.M.1    Terabe, M.2    Sakai, Y.3
  • 2
    • 40949112441 scopus 로고    scopus 로고
    • Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
    • Park JM, Terabe M, Steel JC, et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008;68(6):1979-1987
    • (2008) Cancer Res , vol.68 , Issue.6 , pp. 1979-1987
    • Park, J.M.1    Terabe, M.2    Steel, J.C.3
  • 3
    • 0030749292 scopus 로고    scopus 로고
    • Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
    • Gjertsen MK, Bjorheim J, Saeterdal I, et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72(5):784-790
    • (1997) Int J Cancer , vol.72 , Issue.5 , pp. 784-790
    • Gjertsen, M.K.1    Bjorheim, J.2    Saeterdal, I.3
  • 4
    • 0032433127 scopus 로고    scopus 로고
    • The central role of CD4+ T cells in the antitumor immune response
    • Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-2368
    • (1998) J Exp Med , vol.188 , Issue.12 , pp. 2357-2368
    • Hung, K.1    Hayashi, R.2    Lafond-Walker, A.3
  • 5
    • 65249127501 scopus 로고    scopus 로고
    • Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine
    • •• The first reported use, to our knowledge, of Ad-WT1 for vaccine immunotherapy in vivo
    • Osada T, Woo CY, McKinney M, et al. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res 2009;15(8):2789-2796 •• The first reported use, to our knowledge, of Ad-WT1 for vaccine immunotherapy in vivo.
    • (2009) Clin Cancer Res , vol.15 , Issue.8 , pp. 2789-2796
    • Osada, T.1    Woo, C.Y.2    McKinney, M.3
  • 6
    • 0025605969 scopus 로고
    • Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence
    • Rauscher FJ III, Morris JF, Tournay OE, et al. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990;250(4985):1259-1262
    • (1990) Science , vol.250 , Issue.4985 , pp. 1259-1262
    • Rauscher III, F.J.1    Morris, J.F.2    Tournay, O.E.3
  • 7
    • 0026669131 scopus 로고
    • Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
    • Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992;257(5070):674-678
    • (1992) Science , vol.257 , Issue.5070 , pp. 674-678
    • Drummond, I.A.1    Madden, S.L.2    Rohwer-Nutter, P.3
  • 8
    • 0027278677 scopus 로고
    • Increased expression of the insulin-like growth factor i receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product
    • Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993;90(12):5828-5832
    • (1993) Proc Natl Acad Sci USA , vol.90 , Issue.12 , pp. 5828-5832
    • Werner, H.1    Re, G.G.2    Drummond, I.A.3
  • 9
    • 0027384536 scopus 로고
    • Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
    • Harrington MA, Konicek B, Song A, et al. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;268(28):21271-21275
    • (1993) J Biol Chem , vol.268 , Issue.28 , pp. 21271-21275
    • Harrington, M.A.1    Konicek, B.2    Song, A.3
  • 10
    • 0025291908 scopus 로고
    • The candidate Wilms' tumour gene is involved in genitourinary development
    • Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990;346(6280):194-197
    • (1990) Nature , vol.346 , Issue.6280 , pp. 194-197
    • Pritchard-Jones, K.1    Fleming, S.2    Davidson, D.3
  • 11
    • 0029102956 scopus 로고
    • WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
    • Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14(19):4662-4675
    • (1995) EMBO J , vol.14 , Issue.19 , pp. 4662-4675
    • Englert, C.1    Hou, X.2    Maheswaran, S.3
  • 12
    • 0035827923 scopus 로고    scopus 로고
    • WT1 proteins: Functions in growth and differentiation
    • Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273(2):141-161
    • (2001) Gene , vol.273 , Issue.2 , pp. 141-161
    • Scharnhorst, V.1    Van Der Eb, A.J.2    Jochemsen, A.G.3
  • 13
    • 0025099787 scopus 로고
    • Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
    • Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60(3):509-520
    • (1990) Cell , vol.60 , Issue.3 , pp. 509-520
    • Call, K.M.1    Glaser, T.2    Ito, C.Y.3
  • 14
    • 0032992295 scopus 로고    scopus 로고
    • Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
    • Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90(2):194-204
    • (1999) Jpn J Cancer Res , vol.90 , Issue.2 , pp. 194-204
    • Oji, Y.1    Ogawa, H.2    Tamaki, H.3
  • 15
    • 0026751042 scopus 로고
    • Expression of the Wilms' tumor gene (WT1) in human leukemias
    • Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6(5):405-409
    • (1992) Leukemia , vol.6 , Issue.5 , pp. 405-409
    • Miwa, H.1    Beran, M.2    Saunders, G.F.3
  • 16
    • 0030737629 scopus 로고    scopus 로고
    • High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
    • Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90(3):1217-1225
    • (1997) Blood , vol.90 , Issue.3 , pp. 1217-1225
    • Bergmann, L.1    Miething, C.2    Maurer, U.3
  • 17
    • 33745067420 scopus 로고    scopus 로고
    • WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: An immunohistochemical study
    • Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90
    • (2006) BMC Cancer , vol.6 , pp. 90
    • Netinatsunthorn, W.1    Hanprasertpong, J.2    Dechsukhum, C.3
  • 19
    • 40249116647 scopus 로고    scopus 로고
    • Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis
    • Sera T, Hiasa Y, Mashiba T, et al. Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer 2008;44(4):600-608
    • (2008) Eur J Cancer , vol.44 , Issue.4 , pp. 600-608
    • Sera, T.1    Hiasa, Y.2    Mashiba, T.3
  • 20
    • 44749084527 scopus 로고    scopus 로고
    • WT1 peptide vaccine for the treatment of cancer
    • Oka Y, Tsuboi A, Oji Y, et al. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008;20(2):211-220
    • (2008) Curr Opin Immunol , vol.20 , Issue.2 , pp. 211-220
    • Oka, Y.1    Tsuboi, A.2    Oji, Y.3
  • 21
    • 33947322028 scopus 로고    scopus 로고
    • Immunotherapeutic targeting of Wilms' tumor protein
    • Hutchings Y, Osada T, Woo CY, et al. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 2007;9(1):62-69
    • (2007) Curr Opin Mol Ther , vol.9 , Issue.1 , pp. 62-69
    • Hutchings, Y.1    Osada, T.2    Woo, C.Y.3
  • 23
    • 0034176750 scopus 로고    scopus 로고
    • Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
    • Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95(7):2198-2203
    • (2000) Blood , vol.95 , Issue.7 , pp. 2198-2203
    • Gao, L.1    Bellantuono, I.2    Elsasser, A.3
  • 24
    • 0033966369 scopus 로고    scopus 로고
    • HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
    • Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95(1):286-293
    • (2000) Blood , vol.95 , Issue.1 , pp. 286-293
    • Ohminami, H.1    Yasukawa, M.2    Fujita, S.3
  • 25
    • 61349095387 scopus 로고    scopus 로고
    • Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue
    • Al Qudaihi G, Lehe C, Negash M, et al. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leuk Lymphoma 2009;50(2):260-269
    • (2009) Leuk Lymphoma , vol.50 , Issue.2 , pp. 260-269
    • Al Qudaihi, G.1    Lehe, C.2    Negash, M.3
  • 26
    • 33750291285 scopus 로고    scopus 로고
    • Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein
    • Pinilla-Ibarz J, May RJ, Korontsvit T, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006;20(11):2025-2033
    • (2006) Leukemia , vol.20 , Issue.11 , pp. 2025-2033
    • Pinilla-Ibarz, J.1    May, R.J.2    Korontsvit, T.3
  • 27
    • 23744460167 scopus 로고    scopus 로고
    • Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner
    • Guo Y, Niiya H, Azuma T, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005;106(4):1415-1418
    • (2005) Blood , vol.106 , Issue.4 , pp. 1415-1418
    • Guo, Y.1    Niiya, H.2    Azuma, T.3
  • 28
    • 33645300343 scopus 로고    scopus 로고
    • Defining MHC class II T helper epitopes for WT1 tumor antigen
    • Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006;55(7):850-860
    • (2006) Cancer Immunol Immunother , vol.55 , Issue.7 , pp. 850-860
    • Kobayashi, H.1    Nagato, T.2    Aoki, N.3
  • 29
    • 0036566202 scopus 로고    scopus 로고
    • Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
    • Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99(9):3272-3279
    • (2002) Blood , vol.99 , Issue.9 , pp. 3272-3279
    • Elisseeva, O.A.1    Oka, Y.2    Tsuboi, A.3
  • 30
    • 0034651735 scopus 로고    scopus 로고
    • Cancer immunotherapy targeting Wilms' tumor gene WT1 product
    • • One of the first reports detailing WT1 immunotherapy in vivo for WT1 expressing tumors
    • Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164(4):1873-1880 • One of the first reports detailing WT1 immunotherapy in vivo for WT1 expressing tumors.
    • (2000) J Immunol , vol.164 , Issue.4 , pp. 1873-1880
    • Oka, Y.1    Udaka, K.2    Tsuboi, A.3
  • 31
    • 0034663331 scopus 로고    scopus 로고
    • Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
    • Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96(4):1480-1489
    • (2000) Blood , vol.96 , Issue.4 , pp. 1480-1489
    • Gaiger, A.1    Reese, V.2    Disis, M.L.3    Cheever, M.A.4
  • 33
    • 3042720809 scopus 로고    scopus 로고
    • WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone
    • Nakajima H, Kawasaki K, Oka Y, et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004;53(7):617-624
    • (2004) Cancer Immunol Immunother , vol.53 , Issue.7 , pp. 617-624
    • Nakajima, H.1    Kawasaki, K.2    Oka, Y.3
  • 34
    • 53449089933 scopus 로고    scopus 로고
    • DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance
    • Chaise C, Buchan SL, Rice J, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008;112(7):2956-2964
    • (2008) Blood , vol.112 , Issue.7 , pp. 2956-2964
    • Chaise, C.1    Buchan, S.L.2    Rice, J.3
  • 35
    • 4644289323 scopus 로고    scopus 로고
    • Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    • • The first major, Phase I clinical trial, to our knowledge, evaluating WT1 peptide based vaccine in patients with both hematological and solid malignancies
    • Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101(38):13885-13890 • The first major, Phase I clinical trial, to our knowledge, evaluating WT1 peptide based vaccine in patients with both hematological and solid malignancies.
    • (2004) Proc Natl Acad Sci USA , vol.101 , Issue.38 , pp. 13885-13890
    • Oka, Y.1    Tsuboi, A.2    Taguchi, T.3
  • 36
    • 38049188363 scopus 로고    scopus 로고
    • Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
    • Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111(1):236-242
    • (2008) Blood , vol.111 , Issue.1 , pp. 236-242
    • Rezvani, K.1    Yong, A.S.2    Mielke, S.3
  • 37
    • 69249220181 scopus 로고    scopus 로고
    • A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    • Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113(26):6541-6548
    • (2009) Blood , vol.113 , Issue.26 , pp. 6541-6548
    • Keilholz, U.1    Letsch, A.2    Busse, A.3
  • 38
    • 33745686444 scopus 로고    scopus 로고
    • A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: Safety assessment based on the phase i data
    • Morita S, Oka Y, Tsuboi A, et al. A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006;36(4):231-236
    • (2006) Jpn J Clin Oncol , vol.36 , Issue.4 , pp. 231-236
    • Morita, S.1    Oka, Y.2    Tsuboi, A.3
  • 39
    • 34249106425 scopus 로고    scopus 로고
    • WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma
    • Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007;51(5):519-530
    • (2007) Microbiol Immunol , vol.51 , Issue.5 , pp. 519-530
    • Iiyama, T.1    Udaka, K.2    Takeda, S.3
  • 40
    • 43249090418 scopus 로고    scopus 로고
    • Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
    • Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108(5):963-971
    • (2008) J Neurosurg , vol.108 , Issue.5 , pp. 963-971
    • Izumoto, S.1    Tsuboi, A.2    Oka, Y.3
  • 41
    • 33750823731 scopus 로고    scopus 로고
    • Recent clinical progress in virus-based therapies for cancer
    • Woo CY, Osada T, Clay TM, et al. Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther 2006;6(11):1123-1134
    • (2006) Expert Opin Biol Ther , vol.6 , Issue.11 , pp. 1123-1134
    • Woo, C.Y.1    Osada, T.2    Clay, T.M.3
  • 42
    • 54849406164 scopus 로고    scopus 로고
    • Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus
    • Vujanovic L, Whiteside TL, Potter DM, et al. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother 2009;58(1):121-133
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.1 , pp. 121-133
    • Vujanovic, L.1    Whiteside, T.L.2    Potter, D.M.3
  • 43
    • 0031962522 scopus 로고    scopus 로고
    • High efficiency adenovirus-mediated gene transfer to human dendritic cells
    • Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91(2):392-398
    • (1998) Blood , vol.91 , Issue.2 , pp. 392-398
    • Dietz, A.B.1    Vuk-Pavlovic, S.2
  • 44
    • 0029560716 scopus 로고
    • Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
    • Juillard V, Villefroy P, Godfrin D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995;25(12):3467-3473
    • (1995) Eur J Immunol , vol.25 , Issue.12 , pp. 3467-3473
    • Juillard, V.1    Villefroy, P.2    Godfrin, D.3
  • 45
    • 0029936764 scopus 로고    scopus 로고
    • Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
    • Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2(5):545-550
    • (1996) Nat Med , vol.2 , Issue.5 , pp. 545-550
    • Tripathy, S.K.1    Black, H.B.2    Goldwasser, E.3    Leiden, J.M.4
  • 46
    • 27544510429 scopus 로고    scopus 로고
    • Adenovirus as vehicle for anticancer genetic immunotherapy
    • Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 2005;12(Suppl 1):S84-91
    • (2005) Gene Ther , vol.12 , Issue.SUPPL. 1
    • Gallo, P.1    Dharmapuri, S.2    Cipriani, B.3    Monaci, P.4
  • 47
    • 57349167467 scopus 로고    scopus 로고
    • The current status of adenovirus-based cancer gene therapy
    • Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25(4):462-466
    • (2008) Mol Cells , vol.25 , Issue.4 , pp. 462-466
    • Shirakawa, T.1
  • 48
    • 70450164178 scopus 로고    scopus 로고
    • Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors
    • Seregin SS, Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009;9(12):1521-1531
    • (2009) Expert Opin Biol Ther , vol.9 , Issue.12 , pp. 1521-1531
    • Seregin, S.S.1    Amalfitano, A.2
  • 49
    • 0033056699 scopus 로고    scopus 로고
    • Frequency and stability of chromosomal integration of adenovirus vectors
    • Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999;73(7):6141-6146
    • (1999) J Virol , vol.73 , Issue.7 , pp. 6141-6146
    • Harui, A.1    Suzuki, S.2    Kochanek, S.3    Mitani, K.4
  • 50
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
    • Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893
    • (2008) Lancet , vol.372 , Issue.9653 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3
  • 51
    • 0028328261 scopus 로고
    • Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
    • Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91(10):4407-4411
    • (1994) Proc Natl Acad Sci USA , vol.91 , Issue.10 , pp. 4407-4411
    • Yang, Y.1    Nunes, F.A.2    Berencsi, K.3
  • 53
    • 68949205787 scopus 로고    scopus 로고
    • Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity
    • Osada T, Yang XY, Hartman ZC, et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009;16(9):673-682
    • (2009) Cancer Gene Ther , vol.16 , Issue.9 , pp. 673-682
    • Osada, T.1    Yang, X.Y.2    Hartman, Z.C.3
  • 54
    • 33645086129 scopus 로고    scopus 로고
    • Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
    • Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006;16(3):241-259
    • (2006) Cell Res , vol.16 , Issue.3 , pp. 241-259
    • Xia, D.1    Moyana, T.2    Xiang, J.3
  • 55
    • 8644282802 scopus 로고    scopus 로고
    • Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector
    • Gallo P, Dharmapuri S, Nuzzo M, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113(1):67-77
    • (2005) Int J Cancer , vol.113 , Issue.1 , pp. 67-77
    • Gallo, P.1    Dharmapuri, S.2    Nuzzo, M.3
  • 56
    • 33748867886 scopus 로고    scopus 로고
    • HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination
    • Chan T, Sami A, El-Gayed A, et al. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 2006;13(19):1391-1402
    • (2006) Gene Ther , vol.13 , Issue.19 , pp. 1391-1402
    • Chan, T.1    Sami, A.2    El-Gayed, A.3
  • 57
    • 77951881263 scopus 로고    scopus 로고
    • Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
    • [Epub Ahead of Print]
    • Morse MA, Wei J, Hartman Z, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer 2009 [Epub Ahead of Print]
    • (2009) Int J Cancer
    • Morse, M.A.1    Wei, J.2    Hartman, Z.3
  • 58
    • 25844449779 scopus 로고    scopus 로고
    • Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies
    • Essand M. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies. Acta Oncol 2005;44(6):610-627
    • (2005) Acta Oncol , vol.44 , Issue.6 , pp. 610-627
    • Essand, M.1
  • 59
    • 0035892365 scopus 로고    scopus 로고
    • Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors
    • Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001;94(6):842-849
    • (2001) Int J Cancer , vol.94 , Issue.6 , pp. 842-849
    • Elzey, B.D.1    Siemens, D.R.2    Ratliff, T.L.3    Lubaroff, D.M.4
  • 60
    • 67049155480 scopus 로고    scopus 로고
    • Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
    • Kim S, Lee JB, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009;69(9):938-948
    • (2009) Prostate , vol.69 , Issue.9 , pp. 938-948
    • Kim, S.1    Lee, J.B.2    Lee, G.K.3    Chang, J.4
  • 61
    • 1242293633 scopus 로고    scopus 로고
    • Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin
    • Lane C, Leitch J, Tan X, et al. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64(4):1509-1514
    • (2004) Cancer Res , vol.64 , Issue.4 , pp. 1509-1514
    • Lane, C.1    Leitch, J.2    Tan, X.3
  • 62
    • 2142644402 scopus 로고    scopus 로고
    • CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine
    • Leitch J, Fraser K, Lane C, et al. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004;172(9):5200-5205
    • (2004) J Immunol , vol.172 , Issue.9 , pp. 5200-5205
    • Leitch, J.1    Fraser, K.2    Lane, C.3
  • 63
    • 0034893581 scopus 로고    scopus 로고
    • Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism
    • Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. Gene Ther 2001;8(16):1255-1263
    • (2001) Gene Ther , vol.8 , Issue.16 , pp. 1255-1263
    • Steitz, J.1    Bruck, J.2    Knop, J.3    Tuting, T.4
  • 64
    • 0034095604 scopus 로고    scopus 로고
    • Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: Implications for cancer vaccines
    • Wan Y, Bramson J, Pilon A, et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000;60(12):3247-3253
    • (2000) Cancer Res , vol.60 , Issue.12 , pp. 3247-3253
    • Wan, Y.1    Bramson, J.2    Pilon, A.3
  • 65
    • 0032539190 scopus 로고    scopus 로고
    • Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
    • Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90(24):1894-1900
    • (1998) J Natl Cancer Inst , vol.90 , Issue.24 , pp. 1894-1900
    • Rosenberg, S.A.1    Zhai, Y.2    Yang, J.C.3
  • 66
    • 0033948976 scopus 로고    scopus 로고
    • Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A Phase I/II clinical trial
    • Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur Urol 2000;38(2):208-217
    • (2000) Eur Urol , vol.38 , Issue.2 , pp. 208-217
    • Mincheff, M.1    Tchakarov, S.2    Zoubak, S.3
  • 67
    • 33744479760 scopus 로고    scopus 로고
    • Phase i Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer
    • Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13(6):1185-1191
    • (2006) Mol Ther , vol.13 , Issue.6 , pp. 1185-1191
    • Nemunaitis, J.1    Meyers, T.2    Senzer, N.3
  • 68
    • 41149164895 scopus 로고    scopus 로고
    • Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    • Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31(3):294-309
    • (2008) J Immunother , vol.31 , Issue.3 , pp. 294-309
    • Butterfield, L.H.1    Comin-Anduix, B.2    Vujanovic, L.3
  • 69
    • 0032052293 scopus 로고    scopus 로고
    • Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product
    • Bardeesy N, Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res 1998;26(7):1784-1792
    • (1998) Nucleic Acids Res , vol.26 , Issue.7 , pp. 1784-1792
    • Bardeesy, N.1    Pelletier, J.2
  • 70
    • 4344616068 scopus 로고    scopus 로고
    • Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy
    • Kast WM, Levitsky H, Marincola FM. Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med 2004;2(1):20
    • (2004) J Transl Med , vol.2 , Issue.1 , pp. 20
    • Kast, W.M.1    Levitsky, H.2    Marincola, F.M.3
  • 71
    • 33644879983 scopus 로고    scopus 로고
    • Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide
    • Oh ST, Kim CH, Park MY, et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006;24(15):2860-2868
    • (2006) Vaccine , vol.24 , Issue.15 , pp. 2860-2868
    • Oh, S.T.1    Kim, C.H.2    Park, M.Y.3
  • 72
    • 51049083609 scopus 로고    scopus 로고
    • The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: Implications for immunotherapy
    • Lehe C, Ghebeh H, Al-Sulaiman A, et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008;68(15):6350-6359
    • (2008) Cancer Res , vol.68 , Issue.15 , pp. 6350-6359
    • Lehe, C.1    Ghebeh, H.2    Al-Sulaiman, A.3
  • 73
    • 33644869748 scopus 로고    scopus 로고
    • CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand
    • Salucci V, Mennuni C, Calvaruso F, et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006;63(1):35-41
    • (2006) Scand J Immunol , vol.63 , Issue.1 , pp. 35-41
    • Salucci, V.1    Mennuni, C.2    Calvaruso, F.3
  • 74
    • 70350568201 scopus 로고    scopus 로고
    • A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo
    • Thacker EE, Nakayama M, Smith BF, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009;27(50):7116-7124
    • (2009) Vaccine , vol.27 , Issue.50 , pp. 7116-7124
    • Thacker, E.E.1    Nakayama, M.2    Smith, B.F.3
  • 75
    • 61349182678 scopus 로고    scopus 로고
    • Will changing the face of WT1 make it more attractive to T cells?
    • Kline J. Will changing the face of WT1 make it more attractive to T cells? Leuk Lymphoma 2009;50(2):156-157
    • (2009) Leuk Lymphoma , vol.50 , Issue.2 , pp. 156-157
    • Kline, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.